[Evaluation of prazosin in the treatment of benign hypertrophy of the prostate. A case-control study].
A control-case study conducted in 56 patients, all diagnosed with benign prostate hypertrophy of which 36 were Prazosin-treated patients and the remaining 20 were controls. The patient's mictional signs and symptoms as well as flow parameters were monitored at 3 and 6 months, respectively. We conclude that Prazosin is an alpha-blocker useful in early prostate disorders and when no obstructive urological disease is present.